alector

Alector Files for IPO to Fund Studies of Alzheimer’s, Dementia Drugs

Alector Files for IPO to Fund Studies of Alzheimer’s, Dementia Drugs

Last year, Alector advanced two drugs into early-stage clinical testing.

Alector raises $133M to push neuro-immunology drugs into Alzheimer’s trials

Alector raises $133M to push neuro-immunology drugs into Alzheimer’s trials

With this much investor interest, the round keeps Alector's options open, CBO Sabah Oney says. 

Alector, Abbvie partner on therapies for Alzheimer's

Alector, Abbvie partner on therapies for Alzheimer's

The collaboration could generate up to $225 million for Alector.